University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada Objective: The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid ...

Simponi and Simponi Aria (golimumab) can cause mild to serious ... In studies of Simponi Aria, skin rash was reported as an infusion side effect in people receiving Simponi Aria infusions.

Credit: sergey kolesnikov/Shutterstock. Bio-Thera Solutions has signed an exclusive licence and commercialisation agreement with Intas Pharmaceuticals for the Simponi (golimumab) biosimilar, BAT2506 ...

(Guselkumab + golimumab) is under clinical development by Johnson & Johnson and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% ...

Patients received placebo (Group 1), 50 mg golimumab (Group 2) or 100 mg golimumab (Group 3) subcutaneous injections every 4 weeks. Patients from Groups 1 and 2 with <20% improvement in tender/swollen ...

With the submission of a supplemental biologics license (sBLA) application for golimumab (Simponi), Johnson & Johnson is seeking expanded approval of the anti-TNF biologic to include pediatric ...

Alvotech’s AVT05 showed therapeutic equivalence with golimumab in DAS28-CRP score change at 16 weeks. The positive topline results are the first announced for a golimumab biosimilar. A ...

The retention of second-line golimumab was lower than that of first-line, but still favorable. Treatment persistence is favorable when golimumab is used as a long-term, first-line therapy among ...

Among patients with rheumatic diseases who discontinued treatment with non-tumor necrosis factor (TNF) inhibitors, approximately one-third continued to use golimumab as a third or subsequent line of ...

Roughly one-third of patients with rheumatic disease who discontinued use of non-TNF inhibitors continued treatment with golimumab as their third or subsequent line of therapy at 4 years. Among ...